Clinical Scorecard: Can Portal Hypertension Testing Go Non-invasive?

At a Glance

Key Highlights

• Non-invasive tests may help identify portal hypertension and guide further testing.
• Clinically significant portal hypertension (CSPH) is defined by a hepatic venous pressure gradient (HVPG) of at least 10 mmHg.
• Transient elastography and spleen stiffness measurements can improve diagnostic accuracy.
• Current Baveno VII criteria utilize liver stiffness and platelet count for CSPH assessment.
• AI models show promise for combining imaging and laboratory data for CSPH identification.

Guideline-Based Recommendations

Diagnosis

• HVPG measurement is the reference standard for diagnosing portal hypertension.
• Liver stiffness measurements and platelet counts are used to estimate CSPH likelihood.

Management

• Consider additional testing for patients with indeterminate results from non-invasive assessments.

Monitoring & Follow-up

• Routine laboratory tests may assist in the assessment of portal hypertension.

Risks

• Portal hypertension can lead to complications such as variceal bleeding, ascites, and hepatic encephalopathy.

Patient & Prescribing Data

Patients with chronic liver disease.

Non-invasive tests can help stratify risk and determine the need for invasive procedures.

Clinical Best Practices

• Utilize non-invasive tests for initial risk assessment in portal hypertension.
• Follow a stepwise approach for further testing based on initial results.

Related Resources & Content

• Portal Hypertension & Cirrhosis Review